Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ansofaxine in Major Depressive Disorder
NCT04853407Phase 3Completed
- Sponsor
- Luye Pharma Group
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by Luye Pharma Group. Started Dec 2018; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04853407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853407.